title: Identification and antisense inhibition of a renin-angiotensin system in transgenic cardiomyocytes.
abstract: Cardiac myocytes (AT-1 cells) derived from heart tumors of mice transgenic for an atrial natriuretic factor promoter, SV40 large T-antigen DNA transgene, demonstrate properties consistent with normal cardiac myocytes but retain the capacity to proliferate in culture. We studied the renin-angiotensin system (RAS) and related growth regulation of these cells because AT-1 cells (or transgenically similar cells) may be useful to repair injured myocardium. This study reveals two separate and distinct findings: 1) AT-1 cells proliferate or hypertrophy in response to angiotensin II (ANG II), depending on their competence to proceed through the cell cycle; and 2) AT-1 cells possess components of a RAS, and angiotensinogen antisense experiments suggest that the RAS is functional in these cells. Specifically, AT-1 cells proliferate in response to ANG II in low-serum medium but hypertrophy in response to ANG II when first treated with mitomycin C (at a concentration that inhibits DNA replication but is not cytotoxic). The ANG II-mediated proliferative and hypertrophic responses are inhibited by DuP 753. In addition, there is a significant increase in the protein-to-DNA ratio of cells, which are proliferation-inhibited in the absence of ANG II treatment (20%, P < 0.05). DuP 753 also inhibits this hypertrophy, suggesting that these cells possess a functional RAS. AT-1 cells contain mRNAs for angiotensin-converting enzyme, renin, angiotensinogen, and the AT1 receptor as determined by sequence analysis of polymerase chain reaction amplification products. Antisense oligonucleotides complementary to the angiotensinogen mRNA specifically inhibit angiotensinogen mRNA accumulation and proliferation of AT-1 cells. In summary, these cells contain a growth-regulating RAS, suggesting that such a system may play a significant role in left ventricular hypertrophy.
authors.affiliation: Division of Research, Alton Ochsner Medical Foundation, New Orleans, Louisiana, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Cook
authors.forename: S
authors.initials: S
authors.lastname: Bhandaru
authors.forename: J F
authors.initials: JF
authors.lastname: Giardina
authors.forename: W C
authors.initials: WC
authors.lastname: Claycomb
authors.forename: R N
authors.initials: RN
authors.lastname: Ré
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology / Q000502:physiology; D000808:Angiotensinogen / Q000235:genetics; D000818:Animals; D001483:Base Sequence; D001769:Blood; D002455:Cell Division / Q000187:drug effects; D006984:Hypertrophy; D051379:Mice; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D009206:Myocardium / Q000166:cytology / Q000378:metabolism* / Q000473:pathology; D015345:Oligonucleotide Probes / Q000235:genetics; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects*; D014407:Tumor Cells, Cultured
chemical_list: D015345:Oligonucleotide Probes; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D000808:Angiotensinogen; D000804:Angiotensin II